USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: VASCULAR VISION PHARMACEUTICALS COMPANY
City: WYNANTSKILL
State: NY
Zip+4: 12198-
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $300,000.00 3
STTR Phase I $287,656.00 2

Award List:

kininiogen in Ocular angiogenesis-mediated disorders

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Patricia G. Phillips
Award Amount: $100,000.00
Abstract:
Retinal and choroidal angiogenesis are major causes of vision loss, and the pathogenesis of this angiogenesis process is still unclear. However, several key steps of the angiogenic cascade have been elucidated. In retinal angiogenesis, hypoxia is the initial stimulus that causes upregulation of… More

Enhancing tumor uptake of chemotherapeutics by novel heparin-derived compounds

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Patricia G. Phillips
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): Many cancer patients reportedly have a hypercoagulable state with recurrent thrombosis due to the impact of cancer cells and chemotherapy or radiotherapy on the coagulation cascade. Studies have demonstrated that heparin or its derivatives, low molecular weight… More

Tissue Factor/Vlla modulation in Ocular angiogenesis

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Patricia G. Phillips
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): Diabetic retinopathy is the most common cause of new-onset vision loss in young people in the USA and other industrialized countries, and retinal neovascularization is the significant contributory factor to this vision loss. There is a critical need to develop… More

Nanoparticle targeting of cathepsin-L inhibitor and doxorubicin in breast cancer

Award Year / Program / Phase: 2007 / STTR / Phase I
Agency: HHS
Research Institution: CHILDREN'S MEMORIAL HOSPITAL O
Principal Investigator: Shaker A. Mousa
Award Amount: $128,350.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): The development of resistance to chemotherapy represents an adaptive biological response by tumor cells that leads to treatment failure and patient relapse. There is an urgent need to overcome this problem if treatments are to be successful in eradicating… More

Enabling high dose regional chemotherapy while minimizing systemic toxicity

Award Year / Program / Phase: 2010 / STTR / Phase I
Agency: HHS
Research Institution: Albany College Of Pharmacy
Principal Investigator: Shaker A. Mousa – 518-694-7397
Award Amount: $159,306.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Enabling high dose regional chemotherapy with minimal systemic toxicity Abstract: The primary objective of this proposed study is to develop a filtration system that maximizes the removal (gt90%) of chemotherapeutic agents, such as doxorubicin, from blood while… More